Peroxisome proliferator activated receptor ligands for the treatment of insulin resistance

David Patsouris; Michael Müller; Sander Kersten

Peroxisome proliferator activated receptor ligands for the treatment of insulin resistance

David Patsouris
, Michael Müller
, Sander Kersten

Research output: Contribution to journal › Article › peer-review

37 Citations (Scopus)

Abstract

Peroxisome proliferator activated receptors (PPARs) are a group of ligand-activated transcription factors that play critical roles in the regulation of energy metabolism. Synthetic agonists for these receptors are used in the treatment of type 2 diabetes mellitus and dyslipidemia. Current data linking PPAR and/or PPAR ligands with the treatment of insulin resistance will be critically reviewed, with the focus on important advances over the past year.

Original language	English
Pages (from-to)	1045-1050
Number of pages	6
Journal	Current Opinion in Investigational Drugs
Volume	5
Issue number	10
Publication status	Published - Oct 2004

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Animals
Diabetes Mellitus, Type 2
Humans
Hypoglycemic Agents
Insulin Resistance
Ligands
Peroxisome Proliferator-Activated Receptors

Access to Document

https://pubmed.ncbi.nlm.nih.gov/15535425/

Cite this

@article{f04598d3adc740a3a62675ad9fb04351,

title = "Peroxisome proliferator activated receptor ligands for the treatment of insulin resistance",

abstract = "Peroxisome proliferator activated receptors (PPARs) are a group of ligand-activated transcription factors that play critical roles in the regulation of energy metabolism. Synthetic agonists for these receptors are used in the treatment of type 2 diabetes mellitus and dyslipidemia. Current data linking PPAR and/or PPAR ligands with the treatment of insulin resistance will be critically reviewed, with the focus on important advances over the past year.",

keywords = "Animals, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Insulin Resistance, Ligands, Peroxisome Proliferator-Activated Receptors",

author = "David Patsouris and Michael M{\"u}ller and Sander Kersten",

year = "2004",

month = oct,

language = "English",

volume = "5",

pages = "1045--1050",

journal = "Current Opinion in Investigational Drugs",

issn = "1472-4472",

publisher = "Thomson Scientific Ltd.",

number = "10",

}

TY - JOUR

T1 - Peroxisome proliferator activated receptor ligands for the treatment of insulin resistance

AU - Patsouris, David

AU - Müller, Michael

AU - Kersten, Sander

PY - 2004/10

Y1 - 2004/10

N2 - Peroxisome proliferator activated receptors (PPARs) are a group of ligand-activated transcription factors that play critical roles in the regulation of energy metabolism. Synthetic agonists for these receptors are used in the treatment of type 2 diabetes mellitus and dyslipidemia. Current data linking PPAR and/or PPAR ligands with the treatment of insulin resistance will be critically reviewed, with the focus on important advances over the past year.

AB - Peroxisome proliferator activated receptors (PPARs) are a group of ligand-activated transcription factors that play critical roles in the regulation of energy metabolism. Synthetic agonists for these receptors are used in the treatment of type 2 diabetes mellitus and dyslipidemia. Current data linking PPAR and/or PPAR ligands with the treatment of insulin resistance will be critically reviewed, with the focus on important advances over the past year.

KW - Animals

KW - Diabetes Mellitus, Type 2

KW - Humans

KW - Hypoglycemic Agents

KW - Insulin Resistance

KW - Ligands

KW - Peroxisome Proliferator-Activated Receptors

M3 - Article

C2 - 15535425

SN - 1472-4472

VL - 5

SP - 1045

EP - 1050

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

IS - 10

ER -